Rasio rega marang prakiraan pendapatan: Omeros Corp (OMER)

Simbol resmi perusahaan Omeros Corp. (OMER)

Omeros Corporation (OMER) is implementing robotic systems to accelerate molecular analysis during drug development. The forward P/S history demonstrates market expectations, where the 51.60 metric confirms the current valuation level. Stable demand for neurological drugs makes the asset a defensive tool, independent of macroeconomics. Financial success here is based on pipeline efficiency, ignoring general economic cycles.

OMER Omeros Corp: Rega forward marang dodolan ing interval 14.11.2022 - 17.11.2026

OMER (Omeros Corp): rincian analitis lan laporan miturut indikator

- rega saiki lan proyeksi nilai saham:
- indikator kapitalisasi bursa perusahaan:
Ringkesan analisis perusahaan:Omeros Corporation OMER
Produk asli Omeros

The success of Omeros Corporation (OMER) depends directly on the approval of new therapies and their subsequent insurance coverage, rendering revenue extremely volatile. By analyzing forward price-to-sales dynamics, an investor determines whether expected sales growth justifies the current market capitalization to timely recognize the risk of a sharp equity devaluation should the pace of commercial expansion slow.

Pesaing Omeros Corporation

Multiplikator Forward P/S BIIB (Biogen Idec)|Rasio kapitalisasi marang dodolan sing dikarepake Neurocrine Corp (NBIX)|RGC: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan AXSM (Axsome Therapeutics)|ACAD: Multiplikator Forward P/S|Xenon Pharmaceuticals Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Viking Pharma|SUPN: Rega forward marang dodolan|Multiplikator Forward P/S CPRX|Multiplikator Forward P/S denalitherapeutics.com (DNLI)|Multiplikator Forward P/S HRMY (Harmony Biosciences Inc)|Rasio kapitalisasi marang dodolan sing dikarepake Biohaven (BHVN)|Amylyx Corp - Multiplikator Forward P/S|TRVI - Multiplikator Forward P/S|Praxis Precision Medicines Inc (PRAX) - Rasio rega marang prakiraan pendapatan|AVXL - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan CeriBell|Multiplikator Forward P/S Prothena Corporation plc|Rasio rega marang prakiraan pendapatan Alector Therapeutics (ALEC)|Annexon Inc. - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S NGNE (Neurogene Inc)|AC Immune (ACIU) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Voyager Therapeutics Inc - Multiplikator Forward P/S|Neumora (NMRA) - Multiplikator forward rega marang pendapatan|SCLX: Multiplikator Forward P/S|TVGN - Rasio kapitalisasi marang dodolan sing dikarepake|ACOG (Alpha Cognition Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan cogrx.com (CGTX)|Rasio rega marang prakiraan pendapatan Inhibikase Therapeutics Inc (IKT)|Rasio kapitalisasi marang dodolan sing dikarepake Cassava Sciences|Multiplikator Forward P/S ASRT (Assertio Holdings)|COYA - Multiplikator forward rega marang pendapatan|vistagen.com - Multiplikator Forward P/S|OVID: Rasio rega marang prakiraan pendapatan|Acumen Pharmaceuticals, Inc (ABOS) - Rasio rega marang prakiraan pendapatan|CervoMed Inc - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Alterity Therapeutics Limited|clene.com (CLNN) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan PEPG (PepGen Inc)|Multiplikator Forward P/S jupiterneurosciences.com (JUNS)|Rasio rega marang prakiraan pendapatan Relmada Therapeutics, Inc. RLMD|ANVS: Kapitalisasi marang prakiraan pendapatan|Grace Tx - Multiplikator Forward P/S|AIFF (Firefly Neuroscience Inc) - Kapitalisasi marang prakiraan pendapatan|KLTO: Multiplikator Forward P/S|NeuroSense Therapeutics, Ltd. (NRSN) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Reviva Pharmaceuticals, Inc.|Multiplikator forward rega marang pendapatan metaviatx.com (MTVA)|Multiplikator Forward P/S NRXS|HSDT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Passage Bio, Inc. - Multiplikator forward rega marang pendapatan|bionomics.com.au (NEUP) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Minerva - Multiplikator Forward P/S|Rega forward marang dodolan ATHA (Athira Pharma Inc)|ADXN: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan ALZN|CYCN (Cyclerion Therapeutics Inc.) - Multiplikator Forward P/S|PTIX (Protagenic Therapeutics) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S KTTA|Rasio kapitalisasi marang dodolan sing dikarepake Cortigent|Multiplikator Forward P/S ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Rasio rega marang prakiraan pendapatan|Cara Therapeutics Inc. - Multiplikator Forward P/S|Chromocell Therapeutics (CHRO) - Multiplikator forward rega marang pendapatan|ELYM: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - Multiplikator Forward P/S|Marinus - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S NKGN|NRBO (NeuroBo Pharmaceuticals) - Rega forward marang dodolan|Multiplikator Forward P/S SAGE (Sage Therapeutics Inc)|Rasio kapitalisasi marang dodolan sing dikarepake Synaptogenix Inc. (SNPX)|TRVN - Rasio rega marang prakiraan pendapatan|vigilneuro.com (VIGL) - Multiplikator forward rega marang pendapatan|WENA: Multiplikator Forward P/S|Cerevel Therapeutics, Inc. (CERE) - Multiplikator Forward P/S